AI assistant
Spero Therapeutics, Inc. — Director's Dealing 2021
Feb 10, 2021
34087_dirs_2021-02-10_85e4f586-6909-467f-a616-b556124652fa.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Spero Therapeutics, Inc. (SPRO)
CIK: 0001701108
Period of Report: 2021-02-08
Reporting Person: Aquilo Capital Management, LLC (10% Owner)
Reporting Person: Aquilo Capital, L.P. (10% Owner)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-02-08 | Common Stock, $0.001 Par Value | S | 3000 | $21.7384 | Disposed | 3829209 | Indirect |
Footnotes
F1: The reporting persons are Aquilo Capital, L.P. (the "Fund"), Aquilo Capital Management, LLC ("Aquilo") and Marc R. Schneidman. Aquilo is the general partner and investment adviser of the Fund and other funds managed by Aquilo that hold securities directly for the benefit of their investors. Aquilo may be deemed to beneficially own such securities indirectly as the investment adviser and general partner of the Fund and affiliated funds, and Mr. Schneidman may be deemed to beneficially own them indirectly as the control person of Aquilo. Each of Aquilo, the Fund and Mr. Schneidman disclaims beneficial ownership of such securities except to the extent of his or its pecuniary interest therein.